Cipla Ltd
Cipla Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #45 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Cipla Ltd Q2 FY27 key numbers
- Revenue
- Q2FY27 total revenue from operations: INR 7,404 Cr, down from INR 7,589 Cr in Q2FY26 (slight YoY decline).
As stated in Cipla Ltd's Q2 FY27 investor presentation · published 27 Oct 2026. Reported figures, not investment advice.
Based on Cipla Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2FY27 total revenue from operations: INR 7,404 Cr, down from INR 7,589 Cr in Q2FY26 (slight YoY decline). EBITDA for Q2FY27: INR 1,388 Cr, down from INR 1,895 Cr in Q2FY26 - EBITDA Margin for Q2FY27: 18.7%, down from 25.0% in Q2FY26 - Profit After Tax (PAT) for Q2FY27: INR 878 Cr, down from INR 1,351
From Cipla Ltd's Q2 FY27 earnings-call transcript · updated 27 Oct 2026.
Revenue & Sales Performance
- Q2FY27 total revenue from operations: INR 7,404 Cr, down from INR 7,589 Cr in Q2FY26 (slight YoY decline).
- One India segment achieved highest-ever quarterly revenue: INR 3,516 Cr (Q2FY27).
- South Africa private business revenue: ZAR 1,294 Mn in Q2FY27, growing 1.3x faster than the market.
- Key therapies in India showed double-digit growth YoY (e.g., respiratory +20%, dermatology +16%).
- Consumer Health in One India reported INR 427 Cr revenue.
2 more points from Cipla Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Cipla Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Cipla Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Cipla Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Cipla Ltd said on order book & pipeline — free account, 30 seconds.
Cipla Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹7.4K Cr, net profit ₹852 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Cipla Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Cipla Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Cipla Ltd Q2 FY27 results?
Q2FY27 total revenue from operations: INR 7,404 Cr, down from INR 7,589 Cr in Q2FY26 (slight YoY decline). EBITDA for Q2FY27: INR 1,388 Cr, down from INR 1,895 Cr in Q2FY26 - EBITDA Margin for Q2FY27: 18.7%, down from 25.0% in Q2FY26 - Profit After Tax (PAT) for Q2FY27: INR 878 Cr, down from INR 1,351
What is Cipla Ltd share price analysis?
Cipla Ltd currently shows a neutral. The stock trades at a P/E of 30.6 with a market cap of ₹109,466 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Cipla Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.